Trump Announces Historic Prescription Drug Price Cuts Ahead Of Midterms
President Donald Trump stated that significant reductions in prescription drug prices will be a major issue in the approaching midterm elections. He described these price cuts as a “shock to the system” that will help millions of citizens across the nation.
He announced that Pfizer has agreed to provide state Medicaid programs with access to its drugs at “most-favored-nation” prices. This model ensures the U.S. pays prices similar to the lowest costs available in other developed countries.
The White House provided specific examples of the substantial discounts. These include an 80 percent price reduction for the dermatitis treatment Eucrisa, a 40 percent cut for the rheumatoid arthritis drug Xeljanz, and a 50 percent discount for the migraine medicine Zavzpret.
Trump emphasized that this agreement is only the start of a wider initiative to lower drug costs. He revealed that another major pharmaceutical company is scheduled to meet with him the following week, promising even more dramatic price drops.
When questioned about the political impact of these reductions for the midterm elections, Trump responded, “Huge.” He explained that while he had intended to tackle this complex issue from his first day in office, the COVID-19 pandemic initially redirected the administration’s focus.
The President framed this policy as a decisive move to end “global freeloading,” where the U.S. historically subsidized drug innovation for other nations. He asserted that companies will still earn substantial profits, but Americans will no longer be unfairly charged much higher prices.
Trump concluded by connecting the policy directly to voters’ lives and wallets, suggesting it will influence their choices at the ballot box. He believes the tangible financial relief from lower drug costs will be a powerful factor for the electorate.
